The present disclosure describes methods for treating Type 1 diabetes
mellitus in juveniles. This treatment of Type 1 diabetes is achieved by
administering one or more therapeutic agents to a juvenile in need,
wherein the therapeutic agent is, for example, a competitive inhibitor of
mevalonate synthesis, a competitive inhibitor of
3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, or an inducer
of AMP protein kinase (AMPK) activity. In certain embodiments, juveniles
with Type 1 diabetes are treated with an HMG-CoA reductase inhibitor such
as a statin.